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Abstract: The ability to accurately and reliably quantify viral infection is essential to basic and
translational virology research. Here, we describe a simple and robust automated method for using
fluorescence microscopy to estimate the proportion of virally infected cells in a monolayer. We provide
details of the automated analysis workflow along with a freely available open-source ImageJ plugin,
Infection Counter, for performing image quantification. Using hepatitis C virus (HCV) as an example,
we have experimentally verified our method, demonstrating that it is equivalent, if not better, than the
established focus-forming assay. Finally, we used Infection Counter to assess the anti-HCV activity of
SMBz-CsA, a non-immunosuppressive cyclosporine analogue.
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1. Introduction
Robust and reliable infectivity assays are an essential part of a virologist’s tool kit. The classical
plaque assay provides a tried and tested method of determining virus titer; however, it can only be
applied to cytopathic viruses (plaques arise through virus-mediated cell death within a monolayer) and
typically requires plaques to grow until visible to the naked eye. A related technique, the focus-forming
assay (FFA), can be used to titer non-cytopathic viruses. This relies on the detection of infected cells
by immunostaining for viral antigen or via a genetically encoded fluorescent reporter. However, the
FFA typically requires manual identification and counting of foci by fluorescence microscopy; this is
extremely time consuming, vulnerable to human error and has a limited linear dynamic range.
The FFA is a mainstay of hepatitis C virus (HCV) basic research but the limitations of this
method constrain experimental throughput. As a consequence, various groups have developed
in-house automated quantification methods [1–3]; however, these generally require bespoke equipment
and/or proprietary software, and often possess the same limited dynamic range of the FFA.
In this report we describe Infection Counter, a method for automated quantification of in vitro
HCV replication using a simple and yet robust data analysis pipeline to estimate the percentage
of infected cells. When combined with a plate-reading fluorescence microscope, this provides a
medium/high-throughput assay for basic and translational research. We validate our method using a
known inhibitor of HCV replication and then use Infection Counter to assess the inhibitory activity
of a cyclosporine analogue. Infection Counter is provided as an easy-to-use open-source plugin for
the popular ImageJ or Fiji image analysis software [4,5] that can be adapted to study a wide range of
other viruses.
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2. Materials and Methods
2.1. Cell Lines
Huh-7.5 cells (provided by APATH LLC) were propagated in Dulbecco’s Modified Eagle Medium
(DMEM) + 10% fetal calf serum (FCS) supplemented with penicillin, streptomycin and non-essential
amino acids (all from Life Technologies, Carlsbad, CA, USA).
2.2. Antibodies
Mouse anti-NS5A monoclonal antibody (mAb) 9E10 was a gift from Charles M. Rice, Rockefeller
University, NY, USA. Mouse anti-CD81 mAb 2.20 was a gift from Jane A. McKeating, University of
Birmingham, UK.
2.3. Generation and Propagation of Cell-Culture-Proficient HCV (HCVcc)
Full-length HCVcc RNA genomes were generated by in vitro transcription from XbaI linearized
J6/JFH plasmid template (provided by APATH LLC). To initiate infection, viral RNA was introduced
in to Huh-7.5 cells by electroporation using a BTX830 (Harvard Instruments, Cambridge, UK) [6].
High-titer cell-culture-adapted HCVcc was generated by continuous culture in Huh-7.5 cells for
20 weeks; thereafter, HCVcc stocks were generated by harvesting secreted virus in serum-free DMEM
every 2 h throughout the day for 3 days.
2.4. Infectivity Assay
Huh-7.5 cells were seeded at a density of 1.5 ˆ 104 in to each well of a standard flat bottomed
96-well tissue culture test plate 24 h prior to study. On the day of infection, the cell culture
media in each well was replaced with 50 µL DMEM + 6% FCS and inoculated with 50 µL of
virus (diluted appropriately in serum-free DMEM). After 48 h the cells were washed once in 50 µL
PBS and fixed with 250 µL ice-cold methanol for 10 min. To detect viral antigen, samples were
blocked with 2% bovine serum albumin (BSA) + 0.1% Triton-X 100 and stained with 100 ng/mL
mouse anti-NS5A 9E10, followed by 2 µg/mL goat anti-mouse Alexa Fluor 488 secondary antibody
(Life Technologies). Nuclear DNA was counterstained with 2 µg/mL 41,6-diamidino-2-phenylindole
(DAPI) for 20 min.
2.5. Focus-Forming Assay
Infectivity assays were performed with a serial dilution of HCVcc. Discrete foci of HCV positive
cells were manually counted in replicate wells across a range of virus dilutions. For each dilution
the titer was calculated by multiplying the mean number of foci per well by the dilution factor and a
volume correction, resulting in a value expressed in focus-forming units per mL (FFU/mL). The final
titer was derived by taking the average of three dilutions from across the series.
2.6. Microscopy
Fixed and stained samples in standard 96-well plates were imaged using a Nikon Ti inverted
microscope fitted with a motorized encoded stage for plate-reading. A 3.5 mm by 3.5 mm area of
each well was acquired by image stitching using an ORCA Flash 4 sCMOS camera (Hamamatsu,
Welwyn Garden City, UK), with 405 nm and 488 nm fluorescence illumination provided by a
PE4000 LED (CoolLED, Andover, UK) unit through a multi-band excitation/emission filter cube
(Semrock, Rochester, NY, USA). To ensure optimal imaging, software-based autofocusing was
performed prior to acquiring each well. The images were exported from NIS elements as 8 bit
tif files for analysis in Fiji.
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2.7. Inhibition Experiments
For receptor blockade, Huh-7.5 cells were pre-treated with 50 µL/well anti-CD81 2.20, diluted in
DMEM + 6% FCS, for 1 h at 37 ˝C, after which they were inoculated with 50 µL of virus appropriately
diluted in serum free DMEM. For SMBz-CsA treatment, Huh-7.5 cells were pretreated with 100 µL/well
of SMBz-CsA, diluted in DMEM + 3% FCS, for 1 h at 37 ˝C, after which they were inoculated with
10 µL of appropriately diluted virus, the inoculum was removed after 6 h and the cells re-fed with
DMEM + 3% FCS without drug. In both cases samples were prepared as described in the infectivity
assay, above.
2.8. Statistical Analysis
Statistical analysis and curve fitting was performed using Prism 6 (GraphPad, La Jolla, CA, USA).
Fit models and statistical tests used are indicated in the text and figure legends.
3. Results
3.1. Development of Infection Counter
In a typical HCV in vitro infectivity assay, human hepatoma cells are inoculated with HCVcc for
a defined time period during which virus particles bind to cells, undergo entry and initiate infection.
Experimental observations indicate that HCV protein synthesis and genome replication is detectable
within 10–24 h and de novo virion production is apparent by 18–48 h [6–8]. Therefore, it is possible for
1–2 rounds of replication to occur within 48 h of inoculation. Consequently, at this time point HCVcc
infection manifests as small foci typically containing 1–8 infected cells (Figure 1A,B); these arise both
through limited spread of the virus and division of infected cells. When sufficiently sparse, individual
foci are easily distinguished allowing manual counting and determination of virus titer. However, this
process is labor intensive and vulnerable to user error and bias. Moreover, when spatially crowded,
individual foci cannot be discerned (Figure 1C,D); this limits the linear dynamic range of the assay to a
maximum of ~150 foci per well of a 96-well plate.
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on DAPI-stained nuclei and then estimates the proportion of positive cells based on thresholding of 
associated viral antigen fluorescence signal. A summary of the Infection Counter workflow is shown 
in Figure 2. We provide the software to perform this analysis in the form of an ImageJ plugin along 
with detailed instructions of how to use the plugin (Supplementary Note 1), alternatively the latest 
version and source code of the plugin can be found in the InfectionCounter GitHub repository [9]. 
 
Figure 1. Huh-7.5 human hepatoma cells infected with J6/JFH HCVcc. Cells were fixed 48 h
post-inoculation and stained for viral antigen NS5A (green), nuclear DNA was counterstained with
41,6-diamidino-2-phenylindole (DAPI) (blue). (A) and (C) display representative wells with sparse and
dense infection, respectively; (B) and (D) are enlargements of the highlighted areas. Scale bars 1000 µm
(A) and (C) 200 µm (B) and (D).
Our aim was to build a automated image analysis pipelin to estimate the percentag of infected
cells in fluoresce c microscopy images such as those shown in Figure 1. We devised the ImageJ
plugin Infec io Co nt r, a simpl and yet robust analytical process that segments cells based on
DAPI-st ined nuclei and then estimates the proportion of positive cells based n thresholding of
associated viral antigen fluorescence signal. A summary of the Inf ction Cou ter workflow is shown
in Figure 2. We provide the software to perform this analysis in the form of an ImageJ plugin along
with detailed instructions of how to use the plugin (Supplementary Note 1), alternatively the latest
version and source code of the plugin can be found in the InfectionCounter GitHub repository [9].
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3.2. Validation 
Visual inspection of the processed images suggested that Infection Counter was performing a 
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Infection Counter can, however, underestimate the number of infected cells. An example of this 
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Figure 2. Infection Counter analysis workflow. (A) A representative unprocessed image of Huh-7.5
cells infected with J6/JFH HCVcc, cells were fixed 48 h post-inoculation and stained for viral antigen
NS5A (green), nuclear DNA was counterstained with DAPI (blue), scale bar 200 µm; (B) Cells were
first segmented using the DAPI channel: individual nuclei were identified using the in-built ImageJ
‘Find Maxima’ function, and the locations of these were then used to generate a Voronoi mosaic (in-built
ImageJ ’Voronoi’ function) to approximate individual cell bodies; (C) Following background correction,
the fluorescence intensity of viral antigen associated with each cell was measured and positive cells
were identified using an empirically chosen signal threshold (in this image 4.86% of cells were scored
as positive). The analysis method correctly identified the majority of cell culture proficient (HCVcc)
infected cells (white crosshairs), but miscounted a minority of cells; for instance, the white arrow
indicates a group of four cells that has been scored as two by the algorithm.
3.2. Validation
Visual inspection of the processed images suggested that Infection Counter was performing a
good job of identifying infected cells (Figure 2). In cases where infected cells are tightly clustered,
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Infection Counter can, however, underestimate the number of infected cells. An example of this
highlighted with a white arrow in Figure 2C; visual inspection suggests a group of four infected cells
whereas Infection Counter identifies two infected cells. Therefore, to test whether Infection Counter
was capable of achieving comparable levels of accuracy to manual counting in a FFA, we performed
three independent serial dilutions of HCVcc on Huh-7.5 cells, determined the titer by standard FFA
and analyzed images of replicate wells using Infection Counter (Figure 3). Infection Counter reliably
quantified HCV titers ranging from ~300 to >9000 FFU/mL, indicating a linear dynamic range of at
least thirty-fold, which is comparable to other automated detection method [1–3]. Notably, there was a
near perfect linear relationship between the automated and manual quantification methods (linear
regression; slope = 1.046 ˘ 0.02 when normalized for differences in units); this suggests that a standard
calibration plot could be used to interpolate conventional viral titers from Infection Counter data.
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Figure 3. Serial dilution of HCVcc. Three independent stocks of J6/JFH HCVcc (green, blue and orange
markers) were serially diluted from 1/400 to 1/102400 and inoculated on to Huh-7.5 cells in replicates
of six. The cells were fixed at 48 h, stained for viral antigen and nuclear DNA, and imaged using a
plate-reading fluorescence microscope. The titer of each stock was calculated using the standard FFA
(as described in materials and methods) and he roportio of nfected cells at each concentration was
estimated using Infection Counter. The plot displays concentration of HCVcc (extrapolated from the
viral titer) versus the estimated percentage of infected cells. Linear regression was performed and
produced a line of best of fit which, when normalized for differences in units, exhibited a slope of
1.046, indicating a near-perfect linear relationship between the concentration of HCVcc and estimated
proportion of infected cells. Error bars indicate standard deviation from the mean, n = 6.
To further validate the method we assessed the inhibitory activity of HCV receptor blockade by an
anti-CD81 mAb [10]. Commensurate with the essential role for CD81 in virus entry [11], mAb treatment
potently inhibited HCV infection with an IC50 of ~0.2 µg/mL (1.3 nM) (Figure 4). Quantification by
standard FFA or Infection Counter analysis yielded statistically indistinguishable dose response curves
(F-test, p = 0.29). This confirms that Infection Counter produces data that are equivalent to standard
manual quantification.
Viruses 2016, 8, 201 6 of 10
Viruses 2016, 8, x FOR PEER REVIEW 6 of 18 
 
 
Figure 4. HCV receptor blockade by anti-CD81 monoclonal antibody (mAb). Huh-7.5 cells were 
pretreated for 1 h at 37 °C with a serial dilution of anti-CD81 mAb 2.20, after which the cells were 
inoculated with J6/JFH HCVcc in replicates of four. The cells were fixed after 48 h, stained for viral 
antigen and nuclear DNA, and imaged using a plate-reading fluorescence microscope. The infection 
in each well was quantified using the standard FFA (‘Manual’) and the proportion of infected cells 
was estimated using Infection Counter. The data is expressed as percentage of inhibition relative to 
Huh-7.5 cells treated with an irrelevant control mAb. Sigmoidal curves were fitted using non-linear 
regression (R2 = 0.91 for both curves) and F-test comparison indicated no statistically significant 
difference between the manual and Infection Counter data (p = 0.29). Error bars indicate standard 
deviation from the mean, n = 2. 
3.3. Implementation 
Automated quantification of viral replication provides a medium/high-throughput assay for 
basic and translational research. We exploited this to assess the ability of a cyclosporine (CsA) 
analogue, SMBz-CsA [12-14], to inhibit the HCV life cycle. CsA is an immunosuppressive drug. When 
in complex with its target, cyclophilin A (CypA), it blocks T-cell activation by inhibition of the 
phosphatase calcineurin [15]. CypA is an important cellular co-factor for HCV; it is thought to be 
required for proper assembly of the HCV replication complex, likely through interactions with NS5A 
[16-23]. CsA potently inhibits HCV replication in vitro, this is largely attributed to its ability to block 
CypA-NS5A interactions, which disrupts the formation of the double membrane vesicles necessary 
for HCV replication [16-23]. Moreover, in vivo data demonstrate that the non-immunosuppressive 
CsA analogue SCY635 enhances interferon-α/β production in HCV-infected individuals [21]. A 
further study in chronically infected patients demonstrated that the non-immunosuppressive CsA 
analogue Debio 025 enhanced the anti-HCV activity of pegylated interferon-alpha (PEG IFN-α) [24]. 
We used Infection Counter to assess the inhibitory activity of SMBz-CsA, an alternative non-
immunosuppressive CsA analogue. Huh-7.5 cells were treated with SMBz-CsA before and during a 
6 h inoculation with J6/JFH HCVcc. Importantly, we observed no evidence of cytotoxicity upon 
treatment with SMBz-CsA, as assessed by cell density in each well (data not shown). Virus replication 
was assessed after 48 h using Infection Counter (Figure 5). Consistent with previous reports, SMBz-
CsA exhibited robust inhibition of HCV replication with an IC50 of ~7 μM. In this experiment, the 
drug was only present during early infection (0–6 h), prior to the later events of genome replication 
that are thought to be the principal targets of CsA-mediated inhibition of HCV. This may suggest that 
SMBz-CsA possesses inhibitory activity against earlier stages of the HCV life cycle such as entry, un-
Figure 4. HCV receptor blockade by anti-CD81 monoclonal antibody (mAb). Huh-7.5 cells were
pretreated for 1 h at 37 ˝C with a serial dilution of anti-CD81 mAb 2.20, after which the cells were
inoculated with J6/JFH HCVcc in replicates of four. The cells were fixed after 48 h, stained for viral
antigen and nuclear DNA, and ima ed usi g a plate-reading fluorescence micr scope. The infection
in each ell was quantified using the standard FFA (‘Manu l’) and th proporti of infected cells
was estimated using Infection Counter. The data is expressed as percentage of inhibition relative to
Huh-7.5 cells treated with an irrelevant control mAb. Sigmoidal curves were fitted using non-linear
regression (R2 = 0.91 for both curves) and F-test comparison indicated no statistically significant
difference between the manual and Infection Counter data (p = 0.29). Error bars indicate standard
deviation from the mean, n = 2.
3.3. Implementation
Automated quantification of viral replication provides a medium/high-throughput assay for basic
and translational research. We exploited this to assess the ability of a cyclosporine (CsA) analogue,
SMBz-CsA [12–14], to inhibit the HCV life cycle. CsA is an immunosuppressive drug. W en in complex
with its target, cyclophilin A (CypA), it blocks T-cell activation by inhibition of the phosphatase
calcineurin [15]. CypA is an important cellular co-factor for HCV; it is thought to be required for
proper assembly of the HCV replication complex, likely through interactions with NS5A [16–23].
CsA potently inhibits HCV replication in vitro, this is largely attributed to its ability to block
CypA-NS5A interactions, w ich isrup s the formation of the double membrane vesicles necessary for
HCV replication [16–23]. Moreover, in vivo data demonstrate that the non-immunosuppressive CsA
analogue SCY635 enhances interferon-α/β production in HCV-infected individuals [21]. A further
study in chronically infected patients demonstrated that the non-immunosuppressive CsA analogue
Debio 025 enhanced the anti-HCV activity of pegylated interferon-alpha (PEG IFN-α) [24]. We used
Infection Counter o asses the inhibitory activity of SMBz-CsA, an alternative non-immunosuppressive
CsA analogue. Huh-7.5 cells were treated with SMBz-CsA before and during a 6 h inoculation with
J6/JFH HCVcc. Importantly, we observed no evidence of cytotoxicity upon treatment with SMBz-CsA,
as assessed by cell density in each well (data not shown). Virus replication was assessed after 48 h
using Infection Counter (Figure 5). Consistent with previous reports, SMBz-CsA exhibited robust
inhibition of HCV replication with an IC50 of ~7 µM. In this experiment, the drug was only present
during early infection (0–6 h), prior to the later events of genome replication that are thought to be
the principal targets of CsA-mediated inhibition of HCV. This may suggest that SMBz-CsA possesses
inhibitory activity against earlier stages of the HCV life cycle such as entry, un-coating or initial
translation. Alternatively, SMBz-CsA may possess sufficient intracellular stability to block the late
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stages of replication. A full appreciation of when in the HCV life cycle SMBz-CsA is active will require
detailed time of addition studies.
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Figure 5. The non-i unosuppressive cyclosporine analogue SMBz-CsA inhibits HCVcc replication.
Huh-7.5 cells ere pretreated for 1 h at 37 ˝C with a serial dilution of SMBz-CsA, after which the
cells were inoculated with J6/JFH HCVcc in duplicate. After 6 h the inoculum was removed and the
cells re-fed with media without drug. The samples were fixed after 48 h, stained for viral antigen and
nuclear DNA, and imaged using a plate reading microscope. The infection was then quantified using
Infection Counter. The data is expressed as percentage of inhibition relative to Huh-7.5 cells treated
with dimethyl sulfoxide (DMSO) control. Error bars indicate standard deviation from the mean, n = 3.
4. Discussion
In this report we describe the development, validation and implementation of Infection Counter,
a robust method for automated quantification of in vitro HCV replication. Other groups have
reported similar techniques [1–3], however these have generally required bespoke equipment and/or
commercial software. In contrast, Infection Counter is freely available as an open-source plugin for
ImageJ and Fiji analysis software, and benefits from being relatively simple (for example, there are
only four user-dependent parameters). Whilst the data generated for this report were collected on a
plate-reading microscope, any fluorescence microscope would suffice; therefore, we suggest that this
method is a more accessible alternative to other approaches.
We found Infection Counter to be a robust ethod for easuring viral titer when tested against
a serial dilution of HCVcc; the esti ate percentage of infected cells displayed a near perfect linear
relationship to absolute virus concentration (as easure using anual FFA) over a dynamic range
of at least thirty-fold (Figure 3). e als c re l t I fection Counter for calculating
the inhibitory activity of HCV recept r- l ti- 81 b (Figure 4). The resultant dose
response curves were statistical y indisti , i ting that easurements obtained using
Infection Counter are equivalent t . I portantly, Infection Counter is mor efficient
and les prone to operator er or than , ll ing an increase in throughput of viral
infectivity as ays. For insta ce, ri te plate reading microscope and Infection Counter,
a 96-well plate can be i aged a fi h, perfor ing the same measurements by standard
F A would require many hours of analysis by a i t r t r.
Alternative et s f r edium/high-throughput analysis of viral infection are available.
For instance, viruses encoding luciferase reporters are commonly used in HCV research [25–27].
This method is arguably quicker than a fluorescence based approach, as there are fewer sample
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processing steps and the read out is very rapid. However, not all viruses can accommodate a genetically
encoded reporter. Furthermore, unlike microscopy-based methods, luciferase assays generally require
cell lysis and therefore cannot assess the proportion of infected cells or how they are distributed
in the monolayer. This can be useful information; for instance, a hallmark of HCV replication is
the appearance of distinct foci, containing numerous infected cells (Figures 1 and 2). The size and
distribution of these foci reflects the relative contributions of cell-free and cell-to-cell transmission [28].
Infection Counter can provide the point co-ordinates of virus positive cells (see Supplementary Note 1,
optimisation mode), such data is amenable to spatial statistics analysis [29,30] to better quantify virus
transmission. Whilst this type of analysis is not currently integrated in to Infection Counter, future
releases may include these and other features.
Finally, we implemented Infection Counter to assess the inhibitory activity of SMBz-CsA, a
non-immunosuppressive CsA analogue. Consistent with other reports, SMBz-CsA inhibited HCVcc
replication (Figure 5). This is likely to have occurred through perturbation of CypA-NS5A interactions.
However, given the apparent activity of the drug during early infection other mechanisms may also
be at play. CypA has recently been shown to orchestrate the evasion of intracellular innate immune
responses by human immunodeficiency virus (HIV) [14]. Whether HCV commandeers CypA to a
similar aim remains to be investigated, although it should be noted that CsA has been previously
shown to enhance interferon production in HCVcc infected cells [21,31]. SMBz-CsA exhibits inhibitory
activity against distinct viral pathogens including HCV and HIV, given this, its use as a pan-anti-viral
warrants further study.
The automated analysis method described here is available as an ImageJ plugin. It is free to be
improved, adapted or appropriated, and we urge readers to try it out on their virus of choice.
Supplementary Materials: The following are available online at www.mdpi.com/link/1999-4915/8/7/201/s1,
Supplementary Note 1 (detailed instructions on how to use the plugin), Supplementary Data 1 (an example image
for analysis), Supplementary Software (InfectionCounter.jar file for use with ImageJ/FIJI).
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